Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (122)	3/15/2000 7:36:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 362

Isn't cognitive benefits one end-point in at least one Zomaril PIII trial? Olanzapine Offers Advantages in the Treatment of Early Schizophrenia -------------------------------------------------------------------------------- WESTPORT, Mar 15 (Reuters Health) - Olanzapine provides somewhat greater cognitive benefits in early phase schizophrenia compared with haloperidol and risperidone, according to study findings published in the March issue of the Archives of General Psychiatry. However, the study's authors caution against generalizing the results until they are replicated in a larger sample. In the double-blind study, a multicenter team led by Dr. Scot E. Purdon, of Alberta Hospital Edmonton, Canada, tested the effects of the medications on 65 schizophrenic patients who had been on neuroleptic treatment for no more than 5 years. After a washout period lasting from 2 to 9 days, patients were randomized to receive 5 to 20 mg olanzapine, 4 to 10 mg risperidone or 5 to 20 mg haloperidol per day for 54 weeks. Besides using standard tests to evaluate psychopathologic symptoms and motor signs, the researchers performed a range of tests to assess motor skills, attention span, verbal fluency and reasoning, nonverbal fluency and construction, executive skills and immediate recall. This neuropsychological examination occurred at baseline and at 6, 30 and 54 weeks after treatment began. "Olanzapine produced a substantial gain in cognitive skills greater than that observed with risperidone or haloperidol that was apparent after 6 weeks of treatment and enhanced after 30 and 54 weeks of treatment," the researchers report. Dr. Purdon and colleagues note that an "attempt to qualify the olanzapine improvement in relation to domains of cognitive skill was hampered by limited statistical power after conservative Bonferroni adjustment, but a significant improvement was evident for the immediate recall domain and the Hooper Visual Organization Test." Even though the results of the study are preliminary, they "implicate the value of additional research toward a neuropsychological differentiation of antipsychotic treatments," the authors write. Arch Gen Psychiatry 2000;57:249-258.